Welcome to our dedicated page for Century Therapeutics news (Ticker: IPSC), a resource for investors and traders seeking the latest updates and insights on Century Therapeutics stock.
Century Therapeutics, Inc. (NASDAQ: IPSC) is a clinical-stage biotechnology company pioneering iPSC-derived cell therapies for cancer and autoimmune diseases. This page provides investors and industry observers with direct access to the company's official announcements, including clinical trial progress, financial results, and strategic collaborations.
Our curated news collection enables efficient tracking of material developments in IPSC's Allo-Evasion™ platform and pipeline candidates like CNTY-101. Users will find press releases covering FDA submissions, partnership agreements with leading research institutions, and presentations at major medical conferences.
Key updates include quarterly earnings reports, manufacturing advancements, intellectual property milestones, and peer-reviewed data publications. All content is sourced directly from Century Therapeutics' investor relations communications to ensure accuracy and timeliness.
Bookmark this page for streamlined monitoring of IPSC's progress in developing off-the-shelf cell therapies. Check regularly for updates on preclinical achievements, IND applications, and corporate developments shaping the future of regenerative medicine.
Century Therapeutics (NASDAQ: IPSC) announced significant preclinical advancements in its iPSC-derived cell therapy platform, showcased at the SITC 37th Annual Meeting. Key highlights include effective anti-tumor activity of iPSC-derived CAR gamma delta T cells and the nomination of CNTY-107, targeting Nectin-4 for solid tumors, with an IND filing expected in 2025. The company is enhancing its iNK cell platform, focusing on genetic modifications for improved efficacy and safety. Century is set to provide further insights during a virtual R&D Day on November 11, 2022.
Century Therapeutics (NASDAQ: IPSC) reported its third-quarter 2022 results, revealing a cash position of $395.3 million and a net loss of $30.7 million. The company expects to initiate the Phase 1 ELiPSE-1 trial for CNTY-101 in relapsed/refractory CD19 positive B-cell malignancies soon. R&D expenses increased to $25.9 million, primarily due to higher personnel costs. Century has reduced its GAAP operating expenses guidance for 2022 to $140 million to $145 million, and forecasts a cash runway into 2025.
Century Therapeutics (NASDAQ: IPSC) will host a virtual Research and Development Day on November 11, 2022, from 8:00 AM to 9:30 AM ET. This event will feature presentations from the management team and Dr. Jonathan Rosenberg from Memorial Sloan Kettering Cancer Center, focused on the company's solid tumor strategy and gamma delta iT cell platform. Preclinical data will also be presented at the Society for Immunotherapy of Cancer's 37th Annual Meeting. More details can be found on the company's website under Events & Presentations.
Century Therapeutics (NASDAQ: IPSC) announced that it will present preclinical data from its iPSC-based cell therapy platform at the Society for Immunotherapy of Cancer's 37th Annual Meeting, scheduled for November 8-12, 2022, in Boston. The company will showcase two poster presentations: one focusing on enhancing iNK cell therapies for better anti-tumor efficacy on November 10, and the other on targeting solid tumors with iPSC-derived CAR T cells on November 11. These advancements underline the company's commitment to innovative cancer therapies.
Century Therapeutics (NASDAQ: IPSC) appointed Daphne Quimi and Timothy Walbert to its Board of Directors as part of a strategic move to enhance its leadership. Quimi, currently CFO of Amicus Therapeutics, brings extensive experience in finance and accounting, while Walbert, CEO of Horizon Therapeutics, adds expertise in product commercialization. The announcement also disclosed the resignation of Eli Casdin from the Board, effective October 1, 2022. These changes aim to accelerate the company's development of innovative cell therapies for cancer treatment.
Century Therapeutics (NASDAQ: IPSC) announced CEO Lalo Flores will join the panel discussion on “Next Generation Gene Editing” at Chardan’s 6th Annual Genetic Medicines Conference on October 3, 2022, at 10:30 AM ET. This participation highlights the company's focus on developing iPSC-derived cell therapies for cancer treatment. A live webcast of the event will be available on their website, with a replay archived for a limited time.
Century Therapeutics (NASDAQ: IPSC) announced that Chief Operations Officer Adrienne Farid, Ph.D., will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 9:00 AM ET. The event will be available via live webcast on the company's website, with an archive for later viewing. Century is focused on developing cell therapies for cancer using induced pluripotent stem cells, aiming to improve patient access to innovative treatments. The company emphasizes its expertise in genetic engineering and cellular reprogramming to overcome challenges in the current cell therapy landscape.
Century Therapeutics has received FDA clearance for its CNTY-101 investigational new drug application, targeting relapsed or refractory CD19-positive B-cell malignancies. This marks a significant milestone for the company, which aims to advance the allogeneic cell therapy space with CNTY-101, engineered with six gene edits, Allo-Evasion™ technology, IL-15 support, and a safety switch. The Phase 1 ELiPSE-1 trial is expected to begin in the second half of 2022, assessing the drug's safety and efficacy following conditioning chemotherapy.
Century Therapeutics (NASDAQ: IPSC) reported its Q2 2022 results, ending June 30 with $429.4M in cash. The company is set to initiate the Phase 1 ELiPSE-1 trial for CNTY-101, pending FDA clearance, targeting relapsed/refractory CD19 positive lymphoma. Collaboration revenue stood at $1.4M, while R&D expenses rose to $24.5M due to expanded capabilities. General and administrative costs increased to $8.3M, leading to a net loss of $31M. The company forecasts 2022 operating expenses between $155M and $165M, with a cash runway extending into 2025.
Century Therapeutics (NASDAQ: IPSC) will join the Russell Microcap Index effective June 27, 2022, following the Russell indexes annual reconstitution. This membership lasts one year and includes automatic inclusion in corresponding growth and value style indexes. The Russell indexes are utilized by investment managers and institutional investors, with approximately $12 trillion in assets benchmarked against them. Century Therapeutics focuses on developing iPSC-derived cell therapies for cancer treatment, aiming to overcome limitations of existing therapies.
